CD19 t-haNK- IV Administration

Phase 2

ImmunityBio, Inc. (IBRX)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

IBRXPhase 2$9.3B

CD19 t-haNK- IV Administration Phase 2 Est. Readout

CD19 t-haNK- IV Administration• Relapsed B-Cell Non Hodgkin Lymphoma20

Q2 2027~QConfirmed

CT.gov

00%

Competitive Landscape

0 competitors in Relapsed B-Cell Non Hodgkin Lymphoma

View Full Landscape

Drug Information

Target Indication

Relapsed B-Cell Non Hodgkin Lymphoma

Clinical Trial

NCT07125872

Last updated: 10/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

IBRX

ImmunityBio, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

Prior failed checkpoint inhibitorPhase 3

NSCLC Stage IV

AldoxorubicinPhase 3

Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma

N-803 and BCGPhase 3

Bladder Cancer

N-803Phase 3

Pancreatic Cancer

Intravesical Recombinant Mycobacterium (rMBCG)Phase 2

NMIBC

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts